Reducing Health Disparities

Share

Cancer impacts everyone, but it doesn’t impact everyone equally. We are working to ensure everyone has a fair and just opportunity to prevent, find, treat, and survive cancer. No one should be disadvantaged in their fight against cancer because of how much money they make, the color of their skin, their sexual orientation, their gender identity, their disability status, or where they live.

From ensuring greater diversity among clinical trial participants to improving access to quality, affordable health care, we are asking lawmakers to reduce disparities in cancer care by advancing policies that break down existing barriers.

Black women are 40% more likely to die of breast cancer than white women overall

Latest Updates

July 25, 2024
National

The U.S. House of Representatives and the U.S. Senate introduced the Health Equity and Accountability Act (HEAA) of 2024, which provides a comprehensive set of strategic policy solutions designed to enhance the health and well-being of underserved and marginalized communities.

May 15, 2024
National

Federal legislation that would make it easier for all cancer patients to participate in clinical trials was introduced today in the House. Sponsored by Reps. Raul Ruiz (D-Calif.) and Larry Bucshon (R-Ind.), the Clinical Trial Modernization Act is bipartisan legislation that would increase access to clinical trials by helping remove cost and geographic barriers to patient participation.

May 3, 2024
National

Today, the U.S. Department of Health and Human Services (HHS) finalized a new rule to expand insurance coverage eligibility to Deferred Action for Childhood Arrivals (DACA) recipients.

April 24, 2024
National, New Jersey

The following is a statement from Dr. Karen E. Knudsen, CEO of the American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN), on the passing of U.S. Representative Donald M. Payne Jr. (D-N.J.).

Reducing Health Disparities Resources

Prescription drug costs are a significant burden on cancer patients and survivors, sometimes even leading patients to miss or delay taking prescribed medications. The latest Survivor Views survey explores the role copay assistance programs can play in reducing this burden, and also addresses patient navigation and digital therapeutics.

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on the Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials Draft Guidance for Industry. 

ACS CAN and more than 150 organizations representing patients, providers and health equity advocates sent a letter to Congress urging them to pass the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act into law to remove barriers to clinical trial enrollment.